What is Actos?
Actos Warnings and Alerts
Actos Smoking Gun
Actos Lawsuits
Actos Whistleblower Lawsuit
Our Actos Attorneys
Our Case Results
Contact an Actos Lawyer

Bladder Cancer Information
Bladder Cancer Types
Bladder Cancer Symptoms
Bladder Cancer Treatment
Bladder Cancer Causes

Studies Link Actos to
Bladder Cancer

Medical Terms Dictionary

Report Adverse Side Effects
to FDA MedWatch

Report Adverse Side Effects
to Rxisk.org

Watch Our Video

Tell Us What
Happened to You

*Confirm Email
This field must be blank
*Describe your symptoms
Recent News

Actos Bladder Cancer Lawsuit Verdict Reinstated
July 16, 2015

Takeda Pharmaceuticals Continues Court Ordered Search for Missing Files in Actos Bladder Cancer Litigation
October 17, 2014
Takeda and Eli Lilly Sued Over Actos Bladder Cancer Claims
September 5, 2014

Over 8,000 cases successfully handled across the nation since 1985

Relentless dedication to our clients' causes
More than $1.5 billion recovered*
*Results represent previous cases resolved by Baum Hedlund

We are no longer accepting Actos cases.

The risk of bladder cancer is 40 percent greater in patients
taking Actos for longer than one year.

Takeda Pharmaceutical’s blockbuster diabetes drug Actos (pioglitazone) has been linked to an increased risk of bladder cancer in numerous studies, a find that prompted both France and Germany to suspend prescription of the popular drug. In the US, the Food and Drug Administration (FDA) has warned of this potentially life threatening Actos side effect, but has not pulled the drug off the shelves. The FDA is currently conducting its own investigation into the link between Actos and bladder cancer.

Data linking pioglitazone to bladder cancer was first observed in animal studies back in 1999.

Cancer has been reported in both Actos animal studies and human clinical trials for years, placing the legal obligation on Takeda to update its Actos package insert.

Takeda failed to do so other than an FDA required reference in the Actos package insert to 2005 study results showing that four times as many participants taking Actos had developed bladder cancers, but Takeda also inserted minimizing language stating a causal link had not been established between Actos and bladder cancer. Takeda continues to sell this potentially dangerous drug to diabetes patients at risk for bladder cancer in most countries throughout the world.

If you have taken Actos®, ACTOplus met®, ACTOplus met XR®, or duetact®, and are now suffering from Actos side effects, including bladder cancer, you may be entitled to compensation. It is very important that you find experienced legal counsel to help you through this difficult time and to possibly file an Actos lawsuit on your behalf.

The law firm of Baum, Hedlund, Aristei & Goldman has extensive experience in litigating thousands of personal injury, wrongful death and consumer class action cases against major pharmaceutical companies over the past 25 years. The firm has been on the prevailing side of some of the nation's most highly-publicized cases. Such litigation involves complex evidence and choice of law issues which have been routinely handled by the firm in both state and federal courts.

Baum Hedlund maintains the highest AV® peer review legal rating* and is recognized as a preeminent plaintiff firm that tries or settles serious personal injury and wrongful death lawsuits across the nation. The firm has offices in Los Angeles, New Orleans, Philadelphia, Tallahassee, and Washington, D.C.. Baum Hedlund's staff includes attorneys from top law schools, many of whom have earned the highest attorney AV® Preeminent Peer Review rating*, and who are listed in Best Lawyers in America, Martindale Hubbell's Bar Register of Preeminent Lawyers, Marquis Who's Who in the World and Who's Who in American Law. They can also help clients who only speak Spanish, German, Korean, and Farsi.

Takeda Knew - Actos Smoking Gun Documents

Takeda Protects Actos, Not patients

Takeda to Actos Reps: Don’t Tell – Sell, Sell, Sell

Takeda Surveys Doctors. BladderCancer: What if They Found Out?

FDA Tells Takeda Public Not Adequately Informed About Bladder Cancer Risks

Takeda Battles European Regulatory Authorities’ Push for Clinical Testing of Actos

Placing Actos Sales Before Public Awareness of Bladder Cancer Risk

Actos Whistleblower States the Case Against Takeda